AbCellera Biologics Inc.: Piper Sandler raises target price to $20 from $12
ABCL•Piper Sandler raised its target price for AbCellera Biologics to $20 from $12.
Related News

HyOrc delays third-quarter report to complete financial statements and auditor review
HYOR•

Goldman Sachs expects US 10-year Treasury yield to reach 4.6% by year-end 2027
TLT•

Sono Group holders convert preferred shares into 375,000 ordinary shares
SSM•

Hongchang International delays quarterly report as annual financial reporting remains incomplete
HCIL•

Agomab Therapeutics director David R. Epstein reports $88,679.20 share purchase
AGMB•